Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL

WEDNESDAY, Oct. 10, 2018 -- For patients with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the oral, dual inhibitor of phosphoinositide 3-kinase- δ and -γ, duvelisib, seems effective, according to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news